HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Moderna Inc (MRNA US) - What Would Happen After Moderna Enters China?

China Population Policies Impact on Healthcare Companies Series - Part 1

Everest Medicines (1952.HK) - To Take off Again or to Fall Instead?

Hansoh Pharmaceutical (3692.HK) - Lackluster Pipeline, so Bet on SiRNA?

Jiangsu Hengrui Medicine (600276.CH) 2022/23Q1 - The Situation Is Not as Optimistic as Imagined

Sino Biopharmaceutical (1177.HK) - The Positives and the Negatives

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Bottom-Up

Hansoh Pharmaceutical Group  / Equity Bottom-Up

<ul>
<li>VBP would continue to have an impact on Hansoh’s generic drug business in 2023.Such negative impact would gradually fade from 2024 as big varieties have all been included in VBP.</li>
<li>The core difference between Hansoh and Hengrui is that someone similar to Zhang Lianshan's role arrived late, resulting in a slower start and weaker overall framework for innovation drug business.</li>
<li>
<a href="https://www.smartkarma.com/entities/hansoh-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:23675:1" rel="noopener">Hansoh Pharmaceutical (3692 HK)</a> is still in the process of business transformation. Before the harvest time of innovative drug pipeline comes, Hansoh's valuation growth would still be a long-term story.</li>
</ul>


VBP would continue to have an impact on Hansoh’s generic drug business in 2023.Such negative impact would gradually fade from 2024 as big varieties have all been included in VBP.
The core difference between Hansoh and Hengrui is that someone similar to Zhang Lianshan's role arrived late, resulting in a slower start and weaker overall framework for innovation drug business.

Hansoh Pharmaceutical (3692 HK) is still in the process of business transformation. Before the harvest time of innovative drug pipeline comes, Hansoh's valuation growth would still be a long-term story.


Hansoh Pharmaceutical (3692.HK)- Positive Growth in 2023, but Valuation Turning Point Hasn't Arrived